The first experience of a hybrid approach in the surgical treatment of atrial fibrillation

Abstract

Background: Atrial fibrillation (AF) is the most common arrhythmia in clinical practice and is associated with an increased risk of death, progression of heart failure, and the development of cardiogenic thromboemboli. Despite the significant success in the management of AF in the paroxysmal form, the results of the treatment for patients with persistent forms of AF remain unsatisfactory. Though the surgical approach provides higher rates of efficiency regarding the restoration of a sinus rhythm, transmural lesions are not always attainable, as a result, the rate of AF recurrence in the long-term period remains fairly high. It is also impossible to create ablative patterns to the mitral and tricuspid valves during thoracoscopic epicardial ablation, which can cause the development of recurrent AF, perimitral and typical atrial flutter. Therefore, the development of hybrid approaches combining the advantages of catheter and thoracoscopic techniques is an urgent task of contemporary surgical and interventional arrhythmology.

Aims: to estimate the immediate results of a hybrid approach in the management of patients with persistent AF.

Methods: We report the first experience of a hybrid treatment of patients with persistent AF. 6 patients aged 53-64 years (1 female, 5 males) were included in the study. At the first stage, thoracoscopic epicardial bipolar ablation was performed (modified “GALAXY” protocol); the second stage (in 3 to 6 months after the thoracoscopic stage) included an intracardiac electrophysiological study with three-dimensional endocardial mapping followed by endocardial ablation.

Results: The thoracoscopic stage of the hybrid treatment included ablation according to the “box lesion” scheme using a bipolar irrigation equipment. No lethal outcomes and severe, life-threatening complications were registered. The duration of the inpatient period was 5–10 hospital-days. The 2nd stage of the hybrid treatment was limited to intracardiac electrophysiological examination only in 2 patients. In 4 patients, epicardial radiofrequency ablation was complemented by endocardial radiofrequency exposure. In 3 of the 4 patients who underwent endocardial radiofrequency ablation, catheter ablation of the mitral and cavotricuspid isthmus was required because of the induction of perimitral and typical flutter, respectively. After the 2nd stage of the hybrid treatment, at the time of discharge all the patients maintained a stable sinus rhythm. There were no severe complications or lethal outcomes.

Conclusion: a hybrid approach in the AF management is a safe and effective method of treatment, which combines the advantages of minimally invasive surgery and endocardial intervention in patients with persistent AF. The technique is safe and has acceptable short-term results.

Keywords

ablation technique / atrial fibrillation / surgery / thoracoscopic ablation / hybrid approach

References

[1] Patel NJ, Deshmukh A, Pant S, et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: Implications for healthcare planning. Circulation. 2014;129(23):2371–2379. doi: 10.1161/CIRCULATIONAHA.114.008201

[2] Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the framingham heart study. Circulation. 1998;98(10):946–952. doi: 10.1161/01.cir.98.10.946

[3] Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am College Cardiol. 2001;37(2):371–378. doi: 10.1016/s0735-1097(00)01107-4

[4] Singh SN, Tang XC, Singh BN, et al. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a veterans affairs cooperative studies program substudy. J Am College Cardiol. 2006;48(4):721–730. doi: 10.1016/j.jacc.2006.03.051

[5] Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Therapy. 2009; 26(9):847–857. doi: 10.1007/s12325-009-0066-x

[6] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi: 10.1093/eurheartj/ehaa612

[7] Ватутин Н.Т., Тарадин Г.Г., Гасендич Е.С., и др. О вопросах безопасности применения антиаритмических препаратов // Университетская клиника. 2018. № 3. С. 68–77. [Vatutin NT, Taradin GG, Gasendich ES, et al. On the safety of the use of antiarrhythmic drugs. University clinic. 2018;(3):68–77. (In Russ).]

[8] Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Annals Internal Med. 1999;131(7):492–501. doi: 10.7326/0003-4819-131-7-199910050-00003

[9] Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–2372. doi: 10.1161/CIRCULATIONAHA.110.004747

[10] Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21): 2689–2696. doi: 10.1161/CIRCULATIONAHA.106.653048

[11] Weerasooriya R, Khairy P, Litalien J, et al. Catheter ablation for atrial fibrillation: Are results maintained at 5 years of follow-up? J Am College Cardiol. 2011;57(2):160–166. doi: 10.1016/j.jacc.2010.05.061

[12] Poole JE, Bahnson TD, Monahan KH, et al. Recurrence of atrial fibrillation after catheter ablation or antiarrhythmic drug therapy in the CABANA trial. J Am College Cardiol. 2020;75(25): 3105–3118. doi: 10.1016/j.jacc.2020.04.065

[13] Sebag FA, Simeon E, Miled M, et al. Single-catheter simplified stepwise approach to persistent atrial fibrillation ablation: a feasibility study. Arch Cardiovascular Diseases. 2021; 114(11):707–714. doi: 10.1016/j.acvd.2021.06.012

[14] Yu HT, Kim IS, Kim TH, et al. Persistent atrial fibrillation over 3 years is associated with higher recurrence after catheter ablation. J Cardiovascular Electrophysiology. 2020;31(2): 457–464. doi: 10.1111/jce.14345

[15] Brooks S, Metzner A, Wohlmuth P, et al. Insights into ablation of persistent atrial fibrillation: lessons from 6‐year clinical outcomes. J Cardiovascular Electrophysiology. 2018;29(2): 257–263. doi: 10.1111/jce.13401

[16] Harlaar N, Oudeman MA, Trines SA, et al. Long-term follow-up of thoracoscopic ablation in long-standing persistent atrial fibrillation. Interact Cardiovasc Thorac Surg. 2022;34(6): 990–998. doi: 10.1093/icvts/ivab355

[17] Berger WR, Meulendijks ER, Limpens J, et al. Persistent atrial fibrillation: A systematic review and meta-analysis of invasive strategies. Int J Cardiology. 2019;(278):137–143. doi: 10.1016/j.ijcard.2018.11.127

[18] Wang TK, Liao YW, Wang MT, et al. Catheter vs thoracoscopic ablation for atrial fibrillation: Meta‐analysis of randomized trials. J Arrhythmia. 2020;36(4):789–793. doi: 10.1002/joa3.12394

[19] Gaita F, Scaglione M, Battaglia A, et al. Very long-term outcome following transcatheter ablation of atrial fibrillation. Are results maintained after 10 years of follow up? Ep Europace. 2018; 20(3):443–450. doi: 10.1093/europace/eux008

[20] Pison L, La Meir M, van Opstal J, et al. Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial fibrillation. J Am College Cardiol. 2012;60(1):54–61. doi: 10.1016/j.jacc.2011.12.055

[21] Sunderland N, Maruthappu M, Nagendran M. What size of left atrium significantly impairs the success of maze surgery for atrial fibrillation? Interact Cardiovasc Thorac Surg. 2011;13(3): 332–338. doi: 10.1510/icvts.2011.271999

[22] Kurfirst V, Mokráček A, Bulava A, et al. Two-staged hybrid treatment of persistent atrial fibrillation: Short-term single-centre results. Interact Cardiovasc Thorac Surg. 2014;18(4): 451–456. doi: 10.1093/icvts/ivt538

[23] Gehi AK, Mounsey JP, Pursell I, et al. Hybrid epicardial-endocardial ablation using a pericardioscopic technique for the treatment of atrial fibrillation. Heart Rhythm. 2013;10(1):22–28. doi: 10.1016/j.hrthm.2012.08.044

[24] Thosani AJ, Gerczuk P, Liu E, et al. Closed chest convergent epicardial-endocardial ablation of non-paroxysmal atrial fibrillation--A case series and literature review. Arrhythmia Electrophysiol Rev. 2013;2(1):65. doi: 10.15420/aer.2013.2.1.65

[25] Geršak B, Zembala MO, Müller D, et al. European experience of the convergent atrial fibrillation procedure: Multicenter outcomes in consecutive patients. J Thoracic Cardiovascul Surg. 2014;147(4):1411–1416. doi: 10.1016/j.jtcvs.2013.06.057

[26] Lee LS. Subxiphoid minimally invasive epicardial ablation (convergent procedure) with left thoracoscopic closure of the left atrial appendage. Operative Techniques Thoracic Cardiovascul Surg. 2018;23(4):152–165. doi: 10.1053/j.optechstcvs.2019.04.002

[27] Артюхина Е.А., Таймасова И.А., Ревишвили А.Ш. Катетерная аблация предсердных аритмий у пациентов после торакоскопической аблации персистирующих форм фибрилляции предсердий // Российский кардиологический журнал. 2020. Т. 25, № 7. С. 28–33. [Artyukhina EA, Taimasova IA, Revishvili AS. Catheter ablation of atrial arrhythmias in patients after thoracoscopic ablation of persistent forms of atrial fibrillation. Russian journal of cardiology. 2020;25(7):28–33. (In Russ).] doi: 10.15829/1560-4071-2020-3655

[28] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;(42):373–498. doi: 10.1093/eurheartj/ehaa612

[29] Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020 // Российский кардиологический журнал. 2021. Т. 26, № 7. С. 190–260. [Arakelyan MG, Bokeria LA, Vasilyeva EYu, et al. Fibrillation and atrial flutter. Clinical Guidelines 2020. Russian journal of cardiology. 2021;26(7): 190–260. (In Russ).] doi: 10.15829/1560-4071-2021-4594

[30] Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial. Heart Rhythm. 2017;14(10):e275–e444. doi: 10.1093/europace/eux274

[31] Njoku A, Kannabhiran M, Arora R, et al. Left atrial volume predicts atrial fibrillation recurrence after radiofrequency ablation: A meta-analysis. Ep Europace. 2018;20(1):33–42. doi: 10.1093/europace/eux013

[32] Jeevanantham V, Ntim W, Navaneethan SD, et al. Meta-analysis of the effect of radiofrequency catheter ablation on left atrial size, volumes and function in patients with atrial fibrillation. Am J Cardiol. 2010;105(9):1317–1326. doi: 10.1016/j.amjcard.2009.12.046

[33] Shah D, Haissaguerre M, Jais P, et al. Nonpulmonary vein foci: Do they exist? Pacing Clin Electrophysiol. 2003;26(7 p 2): 1631–1635. doi: 10.1046/j.1460-9592.2003.t01-1-00243.x

[34] Di Biase L, Burkhardt JD, Mohanty P, et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation. 2010;122(2):109–118. doi: 10.1161/CIRCULATIONAHA.109.928903

[35] Kapur S, Barbhaiya C, Deneke Т, et al. Esophageal injury and atrioesophageal fistula caused by ablation for atrial fibrillation. Circulation. 2017;136(13):1247–1255. doi: 10.1161/CIRCULATIONAHA.117.025827

[36] Corrado D, Zorzi A. Risk of catheter ablation for atrial fibrillation. JACC: Clin Electrophysiol. 2017;3(12):1434–1436. doi: 10.1016/j.jacep.2017.07.002

[37] Cox JL. The standard maze-III procedure. Operative Techniques Thoracic CardiovascSurg. 2000;5(1):2–22. doi: 10.1053/oi.2000.3677

[38] La Meir M. New technologies and hybrid surgery for atrial fibrillation. Rambam Maimonides Med J. 2013;4(3):e0016. doi: 10.5041/RMMJ.10116

[39] Syed FF, DeSimone CV, Friedman PA, et al. Left atrial appendage exclusion for atrial fibrillation. Heart Failure Clin. 2016; 12(2):273–297. doi: 10.1016/j.ccl.2014.07.006

[40] Van Laar C, Verberkmoes NJ, van Es HW, et al. Thoracoscopic left atrial appendage clipping: A multicenter cohort analysis. JACC: Clin Electrophysiol. 2018;4(7):893–901. doi: 10.1016/j.jacep.2018.03.009

[41] Healey JS, Crystal E, Lamy A, et al. Left Atrial Appendage Occlusion Study (LAAOS): Results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J. 2005;150(2):288–293. doi: 10.1016/j.ahj.2004.09.054

[42] Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial. J Am College Cardiol. 2014;64(1): 1–12. doi: 10.1016/j.jacc.2014.04.029

Funding

Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий ФМБА РоссииFederal Scientific and Clinical Centre of Specialized Medical Care and Medical Technologies, Federal Biomedical Agency

RIGHTS & PERMISSIONS

Eco-Vector